ProQR Announces Financial Results for the Third Quarter of 2018
07 nov. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
31 oct. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
29 oct. 2018 07h33 HE
|
ProQR Therapeutics N.V.
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in...
ProQR to Present at the Chardan Genetic Medicines Conference
02 oct. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR Announces Presentations at the OTS Annual Meeting
24 sept. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
ProQR gibt positive Zwischenergebnisse aus der klinischen Phase-I/II-Studie zu QR-110 bei Patienten mit LCA10 bekannt und plant den Beginn einer Phase-II/III-Zulassungsstudie
05 sept. 2018 05h46 HE
|
ProQR Therapeutics N.V.
QR-110 zeigte gemessen an Sehschärfe und Umfang der Mobilität eine schnelle und anhaltende Verbesserung des Sehvermögens bei der Mehrheit der Patienten QR-110 war gut verträglich, ohne schwerwiegende...
ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3
05 sept. 2018 05h46 HE
|
ProQR Therapeutics N.V.
Le QR-110 a permis une amélioration rapide et soutenue de la vision chez la majorité des sujets, tant en termes d’acuité visuelle que de mobilité Le QR-110 a été bien toléré sans événements...
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
05 sept. 2018 04h00 HE
|
ProQR Therapeutics N.V.
QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events A...
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
15 août 2018 07h00 HE
|
ProQR Therapeutics N.V.
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th LEIDEN,...
ProQR Announces Financial Results for the Second Quarter of 2018
08 août 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, The Netherlands, Aug. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA...